• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Pharmacoepidemiology and drug safety >Selective serotonin reuptake inhibitor-induced urinary incontinence.
【24h】

Selective serotonin reuptake inhibitor-induced urinary incontinence.

机译：选择性5-羟色胺再摄取抑制剂引起的尿失禁。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

PURPOSE: Irrespective of its cause, urinary incontinence is a medical condition seriously affecting quality of life and is increasingly recognized. In this study, we examined the association between the use of selective serotonin reuptake inhibitors (SSRIs) and urinary incontinence. METHODS: A retrospective follow-up study among starters with an SSRI was performed to estimate the relative and absolute risk for urinary incontinence associated with SSRI use. Data came from the PHARMO database, which includes information on drug dispensing for approximately 450,000 residents living in eight Dutch cities. All patients initially using an SSRI between 1994 and 1998 were selected. The frequency measures for urinary incontinence were estimated by using prescription sequence analysis, where initiation of spasmolytic drugs or absorbent products was used as a measure for urinary incontinence. Besides crude incidence density calculations, Andersen-Gill's model was used in order to control for possible confounding factors and time varying covariates. RESULTS: A total of 13,531 were identified as first time users of an SSRI. Compared to non-exposure, the incidence density ratio for urinary incontinence during SSRI exposure was 1.75 (95% CI 1.56-1.97). Overall, compared to baseline, SSRI use caused 14 extra cases of urinary incontinence per 1000 patients treated per year; the elderly were more at risk resulting in 60 extra cases per 1000 patients per year. The adjusted relative risk for urinary incontinence due to SSRI use was 1.61 (95% CI 1.42-1.82); the risk for sertraline users was 2.76; 95% CI 1.47-5.21). CONCLUSIONS: Exposure to SSRIs is associated with an increased risk for developing urinary incontinence, which can be explained pharmacologically. Approximately 15 out of 1000 patients treated per year with an SSRI developed urinary incontinence. The elderly and users of sertraline are at the highest risk.
机译：目的：无论其原因如何，尿失禁都是一种严重影响生活质量的医学疾病，并且日益受到人们的重视。在这项研究中，我们检查了选择性5-羟色胺再摄取抑制剂（SSRIs）的使用与尿失禁之间的关系。方法：对SSRI初学者进行一项回顾性随访研究，以评估与SSRI使用相关的尿失禁的相对和绝对风险。数据来自PHARMO数据库，该数据库包含有关居住在荷兰八个城市的约45万居民的配药信息。选择1994至1998年间最初使用SSRI的所有患者。尿失禁的频率测量是通过使用处方序列分析来估计的，其中使用痉挛性药物或吸收性产品作为尿失禁的一种测量方法。除了粗略的入射密度计算外，还使用Andersen-Gill模型来控制可能的混杂因素和时变协变量。结果：总共有13,531名被确定为SSRI的首次用户。与未暴露相比，SSRI暴露期间尿失禁的发生密度比为1.75（95％CI 1.56-1.97）。总体而言，与基线相比，每年每治疗1000名患者，SSRI的使用会引起14例尿失禁。老年人的风险更高，每年每1000名患者增加60例。因使用SSRI而导致尿失禁的相对风险调整为1.61（95％CI 1.42-1.82）;舍曲林使用者的风险为2.76; 95％CI 1.47-5.21）。结论：SSRIs暴露与发生尿失禁的风险增加有关，这可以用药理学解释。每年用SSRI治疗的1000名患者中约有15名出现尿失禁。老年人和舍曲林使用者的风险最高。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号